Actively Recruiting
Study to Monitor Immune Responses and Biomarkers in Patients Receiving Cancer Immunotherapy with Immune Checkpoint Blockade
Led by Institut Claudius Regaud · Updated on 2026-06-16
770
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with advanced solid cancers, including non-small cell lung cancer, head and neck cancer, melanoma, bladder cancer, and other tumors where immunotherapy may be effective. This open-label, multi-site study aims to identify and monitor immune system markers linked to responses to immune checkpoint blockade treatments such as anti-PD-1, anti-PD-L1, and anti-CTLA4 antibodies. The study includes patients receiving these treatments as part of routine care or clinical trials. Participants will receive immune checkpoint blockade treatments either alone or combined. Researchers will collect tumor biopsy samples and blood samples at several points before treatment starts, before the 3rd and 5th treatment doses blood only, when treatment stops blood only, at disease progression tumor biopsy only, and after the last treatment dose blood samples twice yearly until study ends. Patients will be followed until their cancer progresses, with survival data collected afterward. During the study, participants will be evaluated for tumor response and immune-related side effects over 18 months. Blood and tumor samples will help assess immune responses under treatment. Safety will be monitored using standard criteria for immune-related adverse events over 12 months. Patients health status and response to therapy will be regularly reviewed, with ongoing follow-up until the study concludes in 2029.
CONDITIONS
Brief Title
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy
Research Team
J
Jean-Pierre DELORD, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here